Open an account

Adaptive Biotechnologies

ADPT · NASDAQ

$24.42+$0.47 (+1.96%)TodayMarket closed ·
Prev close $23.95

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.

Employees
624
Headquarters
Seattle, Washington
Listed
Jun 27, 2019
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
adaptivebiotech.com

ADPT key statistics

Market cap
3.90B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.28M
Volume
1.25M
Open price
$24.07
High today
$24.89
Low today
$23.85
52 Week high
$30.74
52 Week low
$12.00

Adaptive Biotechnologies (ADPT) at a glance

Adaptive Biotechnologies (ADPT) last traded at $24.42, with a market cap of 3.90B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $23.85 and $24.89. The current price is 2.4% above the day's low and 1.9% below its high.

Volume so far is 1.25M shares, below the average of 2.28M shares a day.

Over the past year Adaptive Biotechnologies has ranged from $12.00 to $30.74, and now sits 66% of the way up that range.

Adaptive Biotechnologies met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.10 per share against an estimate of -$0.1364.

The average analyst price target is $28.05, 14.9% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 10 analystsAvg $28.05
Low
$21.21
Now
$24.42
High
$36.75

ADPT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 43.1% on average.

  1. Q3 FY24: reported -$0.22 per share against an estimate of -$0.2932
  2. Q4 FY24: reported -$0.23 per share against an estimate of -$0.2614
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2984
  4. Q2 FY25: reported -$0.17 per share against an estimate of -$0.2435
  5. Q3 FY25: reported $0.06 per share against an estimate of -$0.1492
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.1849
  7. Q1 FY26: reported -$0.12 per share against an estimate of -$0.1632
  8. Q2 FY26: reported -$0.10 per share against an estimate of -$0.1364

ADPT news

  • Vandana Singh

    Adaptive Biotechnologies Business Separation May Unlock Greater Value

  • Vandana Singh

    Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

  • Rishabh Mishra

    Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)

  • Earnings Scheduled For February 5, 2026

  • Avi Kapoor

    Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday

  • Vandana Singh

    Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

  • Vandana Singh

    Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal?

  • Shivdeep Dhaliwal

    Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys

Similar companies

Companies in the same industry as Adaptive Biotechnologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.